[1] |
Yuan Jian, Huang Yanhua.
Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer
[J]. Journal of International Oncology, 2024, 51(6): 338-343.
|
[2] |
Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.
Study on the clinical relationship between inflammatory burden index and gastric cancer
[J]. Journal of International Oncology, 2024, 51(5): 274-279.
|
[3] |
Xie Shuping, Sun Yahong, Wang Chao.
Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer
[J]. Journal of International Oncology, 2024, 51(3): 157-165.
|
[4] |
Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.
Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer
[J]. Journal of International Oncology, 2024, 51(3): 175-180.
|
[5] |
Shao Huifang, Wang Xuehong, Lu Yongfu.
Mechanism of action and clinical significance of CST1 in the progression of gastric cancer
[J]. Journal of International Oncology, 2023, 50(8): 489-492.
|
[6] |
Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu.
Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer
[J]. Journal of International Oncology, 2023, 50(6): 336-341.
|
[7] |
Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.
lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway
[J]. Journal of International Oncology, 2023, 50(4): 202-207.
|
[8] |
Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen.
Correlation between blood lipid level and gastric cancer
[J]. Journal of International Oncology, 2023, 50(3): 183-185.
|
[9] |
Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen.
Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer
[J]. Journal of International Oncology, 2023, 50(2): 112-116.
|
[10] |
Yang Jun, Li Rong, Zeng Jianchang.
Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer
[J]. Journal of International Oncology, 2023, 50(2): 82-86.
|
[11] |
Deng Lili, Duan Xingyu, Li Baozhong.
Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma
[J]. Journal of International Oncology, 2023, 50(12): 751-757.
|
[12] |
Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan.
Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer
[J]. Journal of International Oncology, 2023, 50(11): 677-682.
|
[13] |
Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei.
Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer
[J]. Journal of International Oncology, 2023, 50(10): 631-635.
|
[14] |
Zhao Jianhao, Duan Yanchao.
Research progress in the pathogenesis of extramedullary disease in multiple myeloma
[J]. Journal of International Oncology, 2023, 50(1): 55-59.
|
[15] |
Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.
Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer
[J]. Journal of International Oncology, 2022, 49(5): 276-281.
|